EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reining in strangles: Absence of disease in horses vaccinated with a DIVA‐compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi

Gittan Gröndahl iD, Francesco Righetti iD, Anna Aspán, Joakim Bjerketorp iD, Sara Frosth iD, Lars Frykberg, Karin Jacobsson, Bengt Guss, Romain Paillot iD, Jan-Ingmar Flock iD, Birgitta Henriques-Normark, Andrew S Waller iD

Equine Veterinary Journal · 2026

DOI: 10.1111/evj.70125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Equine Veterinary Journal, 2026. Verfasst von Gittan Gröndahl und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Health and Microbial Strategies, Swedish Veterinary Agency, Uppsala, Sweden. Hauptthemen laut MEDLINE: Horse Diseases, Streptococcal Infections, Streptococcus equi, Bacterial Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intervacc AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Strangles, caused by Streptococcus equi subspecies equi ( S. equi ), is a prevalent infectious disease of horses. This is the first report on the use of a new vaccine, Strangvac, in a natural outbreak of strangles.

Objectives

To measure the effects of Strangvac vaccination during an outbreak of strangles at a Swedish farm. Study Design Longitudinal cohort study.

Methods

Healthy horses ( n = 17) were vaccinated on day 0, which occurred 23 days after strangles was first confirmed in three unvaccinated horses on the same farm. Blood serum samples were collected on day 0, day 28 and day 489. A combined iELISA was used to measure total antibody titres towards the components of the vaccine. Specific antibody levels in blood sera to S. equi were also quantified using the antigen A/C iELISAs, which can differentiate infected from vaccinated animals. Clinical signs were monitored.

Results

All vaccinated horses had increased total antibody titres to CCE, Eq85 and/or IdeE from day 0 (2.50 ± 0.28) to day 28 (3.63 ± 0.31; p < 0.0001). Seropositivity in the antigen A/C iELISA was noted in 8/17 healthy horses on day 0 (prior to vaccination), in 9/16 vaccinates on day 28, and in 3/3 unvaccinated clinical cases on day 28. None of the vaccinated horses developed strangles, but 5/7 of the original vaccinated horses tested seropositive in the A/C iELISA on day 489, which was 377 days after their third vaccination. Main Limitations Aside from the three unvaccinated clinical cases, no unvaccinated control group was available.

Conclusions

Despite adherence to recommended biosecurity measures, serological evidence of exposure to S. equi was demonstrated in half of the vaccinated horses. Notably, all horses vaccinated during the outbreak responded to the vaccine components and remained healthy, suggesting a protective effect of vaccination of healthy horses with Strangvac in outbreak situations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Horse DiseasesStreptococcal InfectionsStreptococcus equiBacterial VaccinesStreptococcal VaccinesAnimalsHorsesLongitudinal StudiesAntibodies, BacterialFemaleSwedenMaleVaccinationDisease OutbreaksStreptococcus

Stichwörter der Autor:innen

StrangvacStreptococcus equihorseoutbreakstranglesvaccine

Substanzen

Antibodies, BacterialBacterial VaccinesStreptococcal Vaccines

Autor:innen und Institutionen

  • Department of Animal Health and Microbial Strategies, Swedish Veterinary Agency, Uppsala, Sweden.
  • Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Department of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
  • Intervacc AB, Stockholm, Sweden.
  • Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden.

ORCID-Profile: Gittan Gröndahl, Francesco Righetti, Joakim Bjerketorp, Sara Frosth, Romain Paillot, Jan-Ingmar Flock, Andrew S Waller

Förderung

  • Intervacc AB

Zitieren

APA

Gröndahl, G., Righetti, F., Aspán, A., Bjerketorp, J., Frosth, S., Frykberg, L., Jacobsson, K., Guss, B., Paillot, R., Flock, J. I., Henriques-Normark, B., & Waller, A. S. (2026). Reining in strangles: Absence of disease in horses vaccinated with a DIVA‐compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi. Equine Veterinary Journal. https://doi.org/10.1111/evj.70125

Vancouver

Gröndahl G, Righetti F, Aspán A, Bjerketorp J, Frosth S, Frykberg L, et al. Reining in strangles: Absence of disease in horses vaccinated with a DIVA‐compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi. Equine Veterinary Journal. 2026. doi:10.1111/evj.70125

BibTeX
@article{Grndahl2026,
  author = {Gröndahl, Gittan and Righetti, Francesco and Aspán, Anna and Bjerketorp, Joakim and Frosth, Sara and Frykberg, Lars and Jacobsson, Karin and Guss, Bengt and Paillot, Romain and Flock, Jan-Ingmar and Henriques-Normark, Birgitta and Waller, Andrew S},
  title = {Reining in strangles: Absence of disease in horses vaccinated with a DIVA‐compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi},
  journal = {Equine Veterinary Journal},
  year = {2026},
  doi = {10.1111/evj.70125}
}
Kostenlos starten →